{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:06:42Z","timestamp":1789553202133,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA186730"],"award-info":[{"award-number":["CA186730"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"DOI":"10.1038\/s41434-026-00644-y","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:37:22Z","timestamp":1789551442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intratumor delivery of a novel plasmid combination induces high levels of metastatic melanoma regression"],"prefix":"10.1038","author":[{"given":"Loree C.","family":"Heller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody C.","family":"Synowiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Jaroszeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3135-1121","authenticated-orcid":false,"given":"Alex","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-3859","authenticated-orcid":false,"given":"Richard","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"644_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1566523214666141121111630","volume":"15","author":"SA Shirley","year":"2015","unstructured":"Shirley SA, Lundberg CG, Li F, Burcus N, Heller R. Controlled gene delivery can enhance therapeutic outcome for cancer immune therapy for melanoma. Curr Gene Ther. 2015;15:32\u201343.","journal-title":"Curr Gene Ther"},{"key":"644_CR2","doi-asserted-by":"crossref","unstructured":"Shi G, Edelblute C, Arpag S, Lundberg C, Heller R. IL-12 gene electrotransfer triggers a change in immune response within mouse tumors. Cancers 2018;10:48\u201367.","DOI":"10.3390\/cancers10120498"},{"key":"644_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575597","volume":"11","author":"KG Nguyen","year":"2020","unstructured":"Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol. 2020;11:575597.","journal-title":"Front Immunol"},{"key":"644_CR4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1006\/mthe.2002.0601","volume":"5","author":"ML Lucas","year":"2002","unstructured":"Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002;5:668\u201375.","journal-title":"Mol Ther"},{"key":"644_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1089\/104454903322624966","volume":"22","author":"ML Lucas","year":"2003","unstructured":"Lucas ML, Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol. 2003;22:755\u201363.","journal-title":"DNA Cell Biol"},{"key":"644_CR6","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1158\/1078-0432.CCR-05-2727","volume":"12","author":"L Heller","year":"2006","unstructured":"Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, et al. Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clin Cancer Res. 2006;12:3177\u201383.","journal-title":"Clin Cancer Res"},{"key":"644_CR7","doi-asserted-by":"crossref","unstructured":"Shi G, Scott M, Mangiamele CG, Heller R. Modification of the tumor microenvironment enhances anti-pd-1 immunotherapy in metastatic melanoma. Pharmaceutics 2022;14:2429\u201347.","DOI":"10.3390\/pharmaceutics14112429"},{"key":"644_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201035","volume":"33","author":"LC Heller","year":"2025","unstructured":"Heller LC, Singh JS, Synowiec JC, Cherukuri PK, Phan N, Shi G, et al. Effective gene immunotherapy for melanoma utilizing an advanced in vivo electrotransfer system. Mol Ther Oncol. 2025;33:201035.","journal-title":"Mol Ther Oncol"},{"key":"644_CR9","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","volume":"26","author":"AI Daud","year":"2008","unstructured":"Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I Trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26:5896\u2013903.","journal-title":"J Clin Oncol"},{"key":"644_CR10","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","volume":"26","author":"AP Algazi","year":"2020","unstructured":"Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res. 2020;26:2827\u201337.","journal-title":"Clin Cancer Res"},{"key":"644_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.annonc.2019.12.008","volume":"31","author":"A Algazi","year":"2020","unstructured":"Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020;31:532\u201340.","journal-title":"Ann Oncol"},{"key":"644_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/2326-6066.CIR-19-0359","volume":"8","author":"SK Greaney","year":"2020","unstructured":"Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, et al. Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses. Cancer Immunol Res. 2020;8:246\u201354.","journal-title":"Cancer Immunol Res"},{"key":"644_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","volume":"25","author":"KM Zak","year":"2017","unstructured":"Zak KM, Grudnik P, Magiera K, Domling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2. Structure. 2017;25:1163\u201374.","journal-title":"Structure"},{"key":"644_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open-source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"644_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep35297","volume":"6","author":"S Horita","year":"2016","unstructured":"Horita S, Nomura Y, Sato Y, Shimamura T, Iwata S, Nomura N. High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1. Sci Rep. 2016;6:35297.","journal-title":"Sci Rep"},{"key":"644_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/cr.2016.77","volume":"27","author":"Z Na","year":"2017","unstructured":"Na Z, Yeo SP, Bharath SR, Bowler MW, Balikci E, Wang CI, et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 2017;27:147\u201350.","journal-title":"Cell Res"},{"key":"644_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14369","volume":"8","author":"S Tan","year":"2017","unstructured":"Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017;8:14369.","journal-title":"Nat Commun"},{"key":"644_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102267","volume":"35","author":"LC Heller","year":"2024","unstructured":"Heller LC, Shi G, Sales Conniff A, Singh J, Mannarino S, Synowiec J, et al. IL-12 and PD-1 peptide combination gene therapy for the treatment of melanoma. Mol Ther Nucleic Acids. 2024;35:102267.","journal-title":"Mol Ther Nucleic Acids"},{"key":"644_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/25763113251377427","volume":"7","author":"LC Heller","year":"2025","unstructured":"Heller LC. Gene electrotransfer and DNA sensing. Bioelectricity. 2025;7:201\u20138.","journal-title":"Bioelectricity"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00644-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00644-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00644-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:37:24Z","timestamp":1789551444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00644-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":19,"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00644-y","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RH, LCH, and MJJ are inventors of patents that cover some of the work reported in this article. RH, AO, LCH, and MJJ have an ownership interest in LifePulse Corp. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declaration"}}]}}